retatrutide triple agonist obesity trial 💉 may be redefining treatment. New data from TRIUMPH-1 showed: 🔥 ~28% average weight loss over 80 weeks 🔥 >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic ⭐️topline results from TRIUMPH-1, a

Once the first dose is administered, the medication travels through the bloodstream to bind with receptors in the pancreas and the brain

(a ) GIPR IC 50 and GLP-1R EC 50 are comparable with both molecules, despite different GLP-1 analogs used

Unfavorable outcomes from AD clinical trials underscore the importance of the timing of treatment

New Human-Use Patent Claims The newly filed applications include claims directed to the potential use of EL-22 and EL-32 to preserve lean muscle mass in patients undergoing obesity-related weight loss treatment, including GLP-1 receptor agonists and dual and triple agonist therapies targeting the GLP-1, GIP, and glucagon pathways

298, E1088E1096